, Neurology, vol.86, issue.16, pp.15-21, 2016.
Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, pp.1430-1438, 2000. ,
The natural history of primary progressive multiple sclerosis, Neurology, vol.73, pp.1996-2002, 2009. ,
New multiple sclerosis phenotypic classification, Eur Neurol, vol.72, pp.1-5, 2014. ,
Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms, Degener Neurol Neuromuscul Dis, vol.4, pp.49-63, 2014. ,
Will the real multiple sclerosis please stand up?, Nat Rev Neurosci, vol.13, pp.507-521, 2012. ,
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis, Lancet Neurol, vol.8, pp.280-91, 2009. ,
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study, Mult Scler J, vol.22, pp.1719-1750, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01414958
Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis, Neuropharmacology, vol.110, pp.644-53, 2015. ,
Structure and function of biotin-dependent carboxylases, Cell Mol Life Sci, vol.70, pp.863-91, 2013. ,
Synthesis and turnover of myelin phospholipids and cholesterol, 1992. ,
Clinical practice. Optic neuritis, N Engl J Med, vol.354, pp.1273-80, 2006. ,
Optic neuritis, its differential diagnosis and management, Open Ophthalmol J, vol.6, pp.65-72, 2012. ,
Management of acute optic neuritis, Lancet, vol.360, pp.1953-62, 2002. ,
The natural history of recurrent optic neuritis, Arch Neurol, vol.61, pp.1401-1406, 2004. ,
The diagnosis and treatment of optic neuritis, Dtsch Arztebl Int, vol.112, pp.616-641, 2015. ,
Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial, Am J Ophthalmol, vol.137, pp.77-83, 2004. ,
The neuro-ophthalmology of multiple sclerosis, Lancet Neurol, vol.4, pp.111-132, 2005. ,
Multiple sclerosis presenting with progressive visual failure, J Neurol Neurosurg Psychiatry, vol.47, pp.943-949, 1984. ,
Walsh & Hoyt's clinical neuro-ophthalmology: the essentials, 2007. ,
Comparison of Snellen and early treatment diabetic retinopathy study charts using a computer simulation, Int J Ophthalmol, vol.9, pp.119-142, 2016. ,
Identification of functional visual field loss by automated static perimetry, Acta Ophthalmol, vol.92, pp.805-814, 2014. ,
Subclinical visual field defects in multiple sclerosis. Demonstration and quantification with automated perimetry, and comparison with visually evoked potentials, J Neurol, vol.227, pp.125-158, 1982. ,
High doses of biotin in chronic progressive multiple sclerosis: a pilot study, Mult Scler Relat Disord, vol.4, pp.159-69, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01251510
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, vol.69, pp.292-302, 2011. ,
ISCEV standard for clinical visual evoked potentials, update). Doc Ophthalmol, vol.120, pp.111-120, 2009. ,
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group, N Engl J Med, vol.326, pp.581-589, 1992. ,
Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNb-1a in multiple sclerosis, Mult Scler, vol.18, pp.1125-1159, 2012. ,
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices, Am J Pathol, vol.176, pp.2682-94, 2010. ,
High dose biotin as treatment for progressive multiple sclerosis, Mult Scler Relat Disord, vol.18, pp.141-144, 2017. ,
Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis, Mult Scler, vol.23, issue.S3, pp.85-426, 2017. ,
Letter to the Editors-Multiple sclerosis and related disorders-Birnbaum et al, Mult Scler Relat Disord, vol.20, p.204, 2017. ,
Relapses during high doses of biotin in progressive multiple sclerosis: a case series, 70th AAN annual meeting, 2018. ,
Annual relapse rates (ARR) in patients with spinal progressive multiple sclerosis treated with MD1003 (high-dose pharmaceutical biotin) ,
, Mult Scler, vol.24, issue.S1, pp.11-117, 2018.